NeuraLight

NeuraLight operates at the intersection of digital biomarkers, neurology clinical research, and AI-enabled drug development. Its stated product is a software platform that captures and analyzes eye movements to produce objective biomarkers for central nervous system disease assessment and trial support. That focus differentiates it from conventional clinical-scale providers, which rely heavily on episodic, subjective assessments, and from neurotechnology companies centered primarily on hardware, stimulation, or consumer wellness. The company’s positioning is particularly relevant to Parkinson’s disease, multiple sclerosis, and broader brain-health programs, where subtle functional changes can be difficult to quantify. Publicly described 2026 results indicate an effort to demonstrate incremental value over established Parkinson’s measurement methods, while the Kariya collaboration shows an application in evaluating the neurological effects of GLP-1 therapies. NeuraLight’s competitive advantage is therefore less about a standalone diagnostic claim and more about becoming measurement infrastructure embedded in drug trials and longitudinal disease monitoring. Its limitations are also clear: public information does not establish regulatory clearances, commercial revenue, or comparative performance against named competitors. With approximately $30.5 million raised across two seed rounds and an employee range of 11–50, it remains an early-stage specialist rather than a scaled category incumbent.

NeuraLight’s trajectory shows a shift from foundational platform creation to clinical and partnership-led validation. Founded in 2021, the company raised $5.5 million in a seed round announced on Oct 28, 2021, followed by a $25 million seed round on May 24, 2022. The larger second round provided substantial capital for developing its precision measurement platform, which uses eye-movement analysis to generate biomarkers for central nervous system diseases. Leadership depth expanded with Edmund Ben Ami becoming co-founder and CEO in 2024, while Rivka Riven Kreitman has served as Chief Innovation Officer since 2021. Scientific credibility became a more visible growth lever in December 2025, when Thomas Südhof joined as scientific co-founder and Olivier Rascol became head of the Scientific Advisory Board. During 2026, the company reported biomarker readouts at AD/PD, published Parkinson’s study findings, announced a GLP-1 research partnership with Kariya, and disclosed a Parkinson’s biomarker collaboration with Mission Therapeutics. These events mark a progression from technology positioning toward disease-specific evidence and pharmaceutical use cases.